Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
Capsid decoys enhance the efficacy of AAV vector transduction after systemic delivery in the presence of neutralizing antibodies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a capsid decoy strategy by Mingozzi et al. demonstrated that mixing gene therapy vectors with empty AAV2-based capsid particles with mutations that ablate primary cell receptor binding could enhance transduction of the gene therapy vector in the presence of low to moderate levels of neutralizing antibodies.76”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [76]
In the citing paper
“Interestingly, empty capsids were used as decoy for anti-AAV antibodies, and thus allowed for ef fi cient transduction of genomecontaining capsids and transgene expression in mice and NHPs (130).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [130]
In the citing paper
“To this end, mutation was introduced into the receptor binding site of capsid to generate an empty capsid mutant, which could not enter target cells but maintained the ability to absorb antibodies (130).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [130]
In the citing paper
“Remarkably, even in the presence of high NAb titer (1:3,000), addition of empty capsids achieved ~45% of transgene expression from the control group that did not receive IVIG.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [130]
In the citing paper
“Another approach consists of proteasome inhibitors, such as carfilzomib and bortezomib, limiting rAAV degradation and antibody presentation; and hydroxychloroquine, inhibiting viral particle recognition by TLR and cGAS [12,[133][134][135].”
From Risk mitigation of immunogenicity: a key to personalized retinal gene therapy (2021) · cites this paper as [133]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 26×
“The three animals dosed with vector formulated in empty capsids— 4001, 4002, and 6001 (all with detectable baseline NAbs; Table 1)— expressed hF.IX at higher levels than the vector only group, between ~300 and 450 ng/ml (Fig.”
BackgroundMethodInfluentialSelf-citationNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 2×
“of AAV8 vectors for hepatocytes compared with AAV2 vectors (20) or the fact that the AAV8 vector carried a self-complementary genome, postulated to drive higher transgene expression levels (22, 25).”
BackgroundMethodClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“Recent work from several laboratories explored the use of alternate AAV serotypes (6, 36) or AAV capsid mutants that escape anti-AAV antibodies (37).”
BackgroundKaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 4×
“Moreover, crossreactivity of anti-AAV antibodies results in neutralization of a wide range of AAV serotypes (5), eliminating the obvious solution of switching AAV serotype.”
BackgroundInfluentialWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 2×
“However, with a prevalence of 30 to 60% in humans (5, 6), neutralizing antibodies (NAbs) to AAV constitute a major obstacle, and other studies have shown that these NAbs, even at relatively low titers, block gene transfer when vector is delivered through the vasculature (2, 7, 8).”
BackgroundAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 3×
“Thus, although increasing the total capsid dose (empty particles and DNA-bearing vector particles) helps to evade anti-AAV humoral responses, it may increase the likelihood of triggering potentially harmful T cell responses against the AAV capsid (1, 2, 11).”
BackgroundSelf-citationGrimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696 · cited 14×
“Conversely, the same excess of AAV2 empty 0 5000 10,000 15,000 20,000 25,000 – – – – 0.5 0.5 0.5 0.5 0X 0X 10X 10X 0X 0X 10X 10X 100 100 77 102 0 9 25 83 * * * IVIg (mg) Empty capsids % Residual expression h F .”
BackgroundInfluentialThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612 · cited 1×
“On the basis of the molecular weight of one AAV particle, ∼3750 kD (18), 1 × 1014 virions correspond to ∼0.”
BackgroundIn vivo genome editing restores haemostasis in a mouse model of haemophilia
Li, H., Haurigot, V., Doyon, Y., Li, T., Wong, S. Y., Bhagwat, A. S., Malani, N., Anguela, X. M., Sharma, R., Ivanciu, L., et al. (2011) · Nature · doi:10.1038/nature10177 · Cited by 548
Self-citationMcCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547 · cited 1×
“of AAV8 vectors for hepatocytes compared with AAV2 vectors (20) or the fact that the AAV8 vector carried a self-complementary genome, postulated to drive higher transgene expression levels (22, 25).”
BackgroundAdeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 500 · cited 1×
“AAV vectors were prepared as previously described (39).”
MethodSelf-citationNathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421 · cited 1×
“of AAV8 vectors for hepatocytes compared with AAV2 vectors (20) or the fact that the AAV8 vector carried a self-complementary genome, postulated to drive higher transgene expression levels (22, 25).”
BackgroundOpie, S. R., Warrington, Agbandje-McKenna, M., Zolotukhin, S., & Muzyczka, N. (2003) · Journal of Virology · doi:10.1128/jvi.77.12.6995-7006.2003 · Cited by 364 · cited 3×
“Because the empty capsid is not immunologically inert, however (13, 14), we performed additional experiments using a noninfectious AAV mutant derived from AAV2 (15), showing that the mutant capsid has markedly lower immunogenicity compared to native empty capsids and is nonetheless equally effective at adsorbing antib…”
BackgroundMethodNathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
Self-citationJiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330 · cited 2×
“However, with a prevalence of 30 to 60% in humans (5, 6), neutralizing antibodies (NAbs) to AAV constitute a major obstacle, and other studies have shown that these NAbs, even at relatively low titers, block gene transfer when vector is delivered through the vasculature (2, 7, 8).”
BackgroundSelf-citationImmune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Self-citationAyuso, E., Mingozzi, F., Montane, J., Leon, X., Anguela, X. M., Haurigot, V, Edmonson, S. A., Africa, L., Zhou, S., High, K. A., et al. (2010) · Gene Therapy · doi:10.1038/gt.2009.157 · Cited by 272 · cited 1×
“Genome-containing vectors and empty AAV capsid particles were purified by cesium chloride gradient centrifugation (40).”
MethodSelf-citationNathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y. C., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G. D., & Davidoff, A. M. (2007) · Blood · doi:10.1182/blood-2006-03-010181 · Cited by 272
Scallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271 · cited 3×
“This is in agreement with previous work showing that AAV vector preparations obtained by column chromatography, thus containing variable amounts of empty capsids, are less prone to neutralization (8).”
BackgroundMethodResultSelf-citationMingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254 · cited 1×
“IX transgene expression after the delivery of AAV8 or AAV2 vectors carrying the same transgene expression cassette (7, 21) and the fact that, in both the AAV2 and AAV8 trials, subjects injected at the highest vector dose (2 × 1012 vg/kg) had similar peak F.”
Self-citationImmune Responses to AAV in Clinical Trials
Mingozzi, F., & High, K. (2007) · Current Gene Therapy · doi:10.2174/156652307782151425 · Cited by 238 · cited 1×
“Therefore, although administration of higher vector doses increases the efficiency of AAV transduction, the activation of capsid-specific T cell immunity, as a function of capsid load (1, 12), may eventually limit the efficacy of gene transfer.”
BackgroundSelf-citationMonteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206 · cited 2×
“Although anti-AAV8 NAb titers higher than 1:1000 are rarely found in humans naïve to AAV vectors (table S1), they are common in subjects dosed with AAV vectors, suggesting that formulation of vector in empty capsids may need to be coupled with other strategies [such as plasmapheresis (17) or pharmacological methods (1…”
BackgroundManufacturing and characterizing AAV-based vectors for use in clinical studies
Wright, J. F. (2008) · Gene Therapy · doi:10.1038/gt.2008.65 · Cited by 205 · cited 2×
“We thus focused on the differences in AAV vector preparations, because the vector used in the AAV2 study was devoid of empty AAV capsids (9), whereas the vector used in the AAV8 study contained up to 10X empty capsids (10).”
BackgroundMethodSelf-citationPien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192 · cited 2×
“Because the empty capsid is not immunologically inert, however (13, 14), we performed additional experiments using a noninfectious AAV mutant derived from AAV2 (15), showing that the mutant capsid has markedly lower immunogenicity compared to native empty capsids and is nonetheless equally effective at adsorbing antib…”
BackgroundMethodSelf-citationPEG conjugation moderately protects adeno‐associated viral vectors against antibody neutralization
Lee, G. K., Maheshri, N., Kaspar, B., & Schaffer, D. V. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20562 · Cited by 169 · cited 1×
“Additional strategies tested include the conjugation of AAV vectors with polyethylene glycol (34, 35), which was only partially beneficial at protecting the virus from neutralization and led to reduced infectivity.”
MethodEnhancement of Adeno-Associated Virus Infection by Mobilizing Capsids into and Out of the Nucleolus
Johnson, J. S., & Samulski, R. J. (2009) · Journal of Virology · doi:10.1128/jvi.02309-08 · Cited by 162 · cited 1×
“Empty AAV capsids, however, do enter target cells (24); thus, one limitation of our strategy is that increasing the capsid dose is likely to add to the total amount of capsid antigen being presented on MHC class I (13, 14) and contribute to the recognition of transduced cells by capsid-specific CD8+ T cells (1, 2, 11).”
BackgroundDrinking a lot is good for dendritic cells
Norbury, C. C. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02335.x · Cited by 160 · cited 1×
“One potential limitation of this strategy derives from the fact that professional antigenpresenting cells can engulf antigens by pinocytosis (30), in addition to receptor-mediated uptake, thus making noninfectious mutant capsids potentially immunogenic, at least to some extent.”
BackgroundAllay, J. A., Sleep, S., Long, S., Tillman, D. M., Clark, R., Carney, G., Fagone, P., McIntosh, J. H., Nienhuis, A. W., Davidoff, A. M., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.202 · Cited by 152 · cited 2×
“We thus focused on the differences in AAV vector preparations, because the vector used in the AAV2 study was devoid of empty AAV capsids (9), whereas the vector used in the AAV8 study contained up to 10X empty capsids (10).”
BackgroundMethodHurlbut, G. D., Ziegler, R. J., Nietupski, J. B., Foley, J. W., Woodworth, L. A., Meyers, E., Bercury, S. D., Pande, N. N., Souza, D. W., Bree, M. P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.175 · Cited by 142 · cited 1×
“Experiments in nonhuman primates, which have a similar anti-AAV antibody profile to humans (26), support the validity of our hypothesis.”
ResultMingozzi, F., Chen, Y., Edmonson, S. C., Zhou, S., Thurlings, R. M., Tak, P. P., High, K. A., & Vervoordeldonk, M. J. (2013) · Gene Therapy · doi:10.1038/gt.2012.55 · Cited by 138 · cited 19×
“Using a cell-based assay to measure anti-AAV8 NAbs (16), we demonstrated that empty capsids greatly reduce neutralizing activity of intravenous immunoglobulin (IVIg) and human serum in vitro (fig.”
BackgroundMethodInfluentialSelf-citationArruda, V. R., Stedman, H. H., Haurigot, V., Buchlis, G., Baila, S., Favaro, P., Chen, Y., Franck, H. G., Zhou, S., Wright, J. F., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261156 · Cited by 117 · cited 2×
“Intravascular delivery of AAV vectors is a safe, simple, and minimally invasive gene delivery approach that can be used to target multiple tissues (1, 2, 4).”
BackgroundSelf-citationFinn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115 · cited 2×
“Because the empty capsid is not immunologically inert, however (13, 14), we performed additional experiments using a noninfectious AAV mutant derived from AAV2 (15), showing that the mutant capsid has markedly lower immunogenicity compared to native empty capsids and is nonetheless equally effective at adsorbing antib…”
BackgroundMethodSelf-citationMingozzi, F., Chen, Y., Murphy, S. L., Edmonson, S. C., Tai, A., Price, S. D., Metzger, M. E., Zhou, S., Wright, J. F., Donahue, R. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.84 · Cited by 112
Self-citationEnhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
Bartel, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00204 · Cited by 108 · cited 1×
“Recent work from several laboratories explored the use of alternate AAV serotypes (6, 36) or AAV capsid mutants that escape anti-AAV antibodies (37).”
BackgroundUtility of PEGylated recombinant adeno-associated viruses for gene transfer
Le, H. T., Yu, Q.-C., Wilson, J. M., & Croyle, M. A. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.07.019 · Cited by 82 · cited 1×
“Additional strategies tested include the conjugation of AAV vectors with polyethylene glycol (34, 35), which was only partially beneficial at protecting the virus from neutralization and led to reduced infectivity.”
MethodMimuro, J., Mizukami, H., Hishikawa, S., Ikemoto, T., Ishiwata, A., Sakata, A., Ohmori, T., Madoiwa, S., Ono, F., Ozawa, K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.258 · Cited by 74 · cited 1×
“Similarly, use of balloon catheters combined with saline flush has shown some efficacy but only for liver gene transfer in the presence of low to moderate NAb titers (33).”
BackgroundMurphy, S. L., Li, H., Zhou, S., Schlachterman, A., & High, K. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300334 · Cited by 62
Self-citationBenson, G. M., Auerswald, G., Elezović, I. V., Lambert, T., Ljung, R. C. R., Morfini, M., Remor, E., & Šalek, S. Z. (2012) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2012.01754.x · Cited by 56 · cited 1×
“6 mg of protein, less than the standard doses of recombinant proteins administered repeatedly, for example, in the clinical management of hemophilia (19).”
BackgroundHigh-throughput Screening and Biophysical Interrogation of Hepatotropic AAV
Murphy, S. L., Bhagwat, A., Edmonson, S., Zhou, S., & High, K. A. (2008) · Molecular Therapy · doi:10.1038/mt.2008.210 · Cited by 20
Self-citation
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Self-citationEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Self-citation
Metadata
- Authors
- Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., Howard, C., Tai, A., Podsakoff, G. M., Zhou, S., Basner-Tschakarjan, E., Wright, J. F., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Department of Pediatrics and Center for Cellular and Molecular Therapeutics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA.
- Corresponding author
- Mingozzi, Federico
- High, Katherine A.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2013-07-17
- Volume
- 5
- Issue
- 194
- Pages
- 194ra92-194ra92
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC4095828
- OpenAlex
- W2164545730
- Cited by
- 355
- References
- 44
- Citations by year
- 2026: 14 · 2025: 35 · 2024: 28 · 2023: 34 · 2022: 33 · 2021: 29 · 2020: 23 · 2019: 28 · 2018: 24 · 2017: 30 · 2016: 16 · 2015: 27 · 2014: 26 · 2013: 7
- FWCI
- 16.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Heart, Lung, and Blood Institute (P01HL078810)
- National Center for Research Resources (G20RR030997)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- adeno-associated virus vectors, neutralizing antibodies, capsid mutants, antibody adsorption, systemic gene delivery, nonhuman primate model
- MeSH terms
- Dependovirus, Animals, Antibodies, Viral, Capsid, Humans, Macaca mulatta, Male, Mice, Inbred C57BL, Mutation, Neutralization Tests, Gene Transfer Techniques, Mice, Immunity, Humoral, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.